Listen as Jansen Jacob, Frank Dollard and Steve Garland discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice; how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are trying to squeeze costs to meet the needs of a larger proportion of people requiring more medicines.
About the In...
Listen as Jansen Jacob, Frank Dollard and Steve Garland discuss the ways in which pharma and biotech companies are getting control back over their supply chain and the opportunities they are seeing from best practice; how the importance of quality and efficiency, including moves towards new low-cost regions in the West, are reducing risk for manufacturers whilst governments are trying to squeeze costs to meet the needs of a larger proportion of people requiring more medicines.
About the Interviewees:
Jansen Jacob is a Vice President at PharmaVentures.
Jansen is a healthcare transactions professional with nearly 20 years in the life science sector with expertise in M&A, licensing, business strategy, commercial due-diligence and deal structuring. At PharmaVentures, Jansen has played a key role in the divestment of manufacturing and R&D businesses on behalf of top 10 large pharmaceutical companies, resulting in multi-million dollar deals. Over the years he has also worked on a diverse range of assignments including licensing, valuation and strategy projects.
Frank Dollard is a Senior Advisor at PharmaVentures.
Frank has a 40-year track-record of success and innovation in the Pharmaceutical Industry working for Glaxo, BMS and Pliva. His main experiences cover Manufacturing, Quality Management, Commercial, Supply-Chain and Procurement (Strategic Sourcing) within the ethical & generic pharmaceutical and devices industry. He has formed and led teams in Europe/USA/Latin America and the Pacific Rim. Frank is a chemistry graduate from the University of Liverpool. Since joining PharmaVentures, Frank has opined on multiple divestment projects, including the recent sale of Novartis’ manufacturing plants to Siegfried.
Steve Garland is an Expert Advisor at PharmaVentures.
With over 35 years’ experience in the biologics industry Steve’s career has covered the manufacturing, process development, business development and general management of vaccine (human and animal), recombinant proteins, monoclonal antibodies and cell and gene therapy product supply. Steve has worked in both the CDMO and multi-product organisations and has extensive experience of microbial, yeast and mammalian cell culture systems ranging from less than 500mL to 12,000L scale using single use disposable and purpose designed and built stainless steel equipment.
A microbiologist by education Steve has lived and worked in the Netherlands. He has led technology transfer projects into, out of and within the UK, has worked as a process expert on facility design and build within and without of the UK and has been process/facility lead on several M&A assignments.
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
